The Global Mental Health Crisis

The 19th century saw a wave of asylum construction in Western industrialized countries, driven by the "moral treatment" movement that advocated humane, therapeutic environments for the mentally ill. Pioneered by reformers such as William Tuke in England and Dorothea Dix in the United States, these asylums were initially designed as comfortable retreats. However, by the late 19th century, overcrowding, underfunding, and neglect turned many into custodial institutions where patients faced poor conditions, abuse, and long-term confinement.

French researchers synthesized chlorpromazine (marketed as Thorazine), the first effective antipsychotic drug. Chlorpromazine could rapidly reduce psychotic symptoms such as hallucinations and delusions, enabling many patients to leave hospitals who could not have been managed in community settings before. The discovery revolutionized psychiatric treatment and was a major catalyst for deinstitutionalization, demonstrating that mental illness could be treated pharmacologically.

The population of US state mental hospitals reached its historic peak at approximately 559,000 patients. Over the following decades, this number would decline by more than 90 percent as deinstitutionalization accelerated. The peak represented the culmination of over a century of institutional psychiatry and marked the beginning of one of the most significant transformations in mental health care — the shift from institutional to community-based treatment.

President John F. Kennedy signed the Community Mental Health Act, the first major US federal legislation aimed at replacing institutional care with community-based mental health centers. Kennedy, whose sister Rosemary had been institutionalized, called for a "bold new approach" to mental illness. The act funded the construction of community mental health centers nationwide, though many were never built due to inadequate funding. The gap between the policy vision and its implementation would have profound consequences.

The deinstitutionalization movement accelerated dramatically in the 1970s, driven by antipsychotic medications, civil rights litigation (including the right-to-treatment cases), and state government cost-cutting. Between 1955 and 1980, the US state hospital population dropped from 559,000 to approximately 150,000. However, the promised community mental health centers were never fully funded or built. Many former patients were discharged without adequate support, contributing to rising homelessness and incarceration of mentally ill individuals.

The US Food and Drug Administration approved fluoxetine (Prozac), the first selective serotonin reuptake inhibitor (SSRI) antidepressant. Prozac and subsequent SSRIs (Zoloft, Paxil, Celexa) became among the most prescribed medications in the world, sparking a cultural phenomenon and debate about the medicalization of sadness and anxiety. The era marked a shift in public discourse, with celebrities discussing depression openly and awareness of mental health issues entering the mainstream.

The United States enacted the Mental Health Parity Act of 1996, requiring that annual and lifetime dollar limits for mental health benefits be no lower than limits for medical and surgical benefits. The law was a landmark recognition that mental health conditions should be treated equivalently to physical health conditions by insurers. Subsequent laws expanded parity protections, including the 2008 Mental Health Parity and Addiction Equity Act and provisions in the 2010 Affordable Care Act.

The World Health Assembly adopted the Comprehensive Mental Health Action Plan 2013-2030, committing WHO member states to reduce suicide rates by one-third, increase service coverage for severe mental disorders, and integrate mental health into primary care. The plan represented the first global consensus on mental health targets and reflected growing recognition that mental disorders account for a significant share of the global burden of disease — nearly one in five years lived with disability.

The Global Burden of Disease study estimated that approximately 970 million people worldwide were living with a mental disorder, with anxiety and depressive disorders the most common. Mental disorders were identified as a leading cause of disability globally. The data underscored that mental health conditions affect people across all regions, income levels, and demographic groups, and that the treatment gap — the difference between those who need care and those who receive it — exceeded 50 percent in most countries.

The COVID-19 pandemic and associated lockdowns, social isolation, economic disruption, and grief triggered a global surge in anxiety and depression. The World Health Organization reported a 25 percent increase in the prevalence of anxiety and depressive disorders worldwide in 2020 alone. Young people, women, and healthcare workers were disproportionately affected. The pandemic exposed the fragility of mental health support systems globally and accelerated the adoption of telehealth and digital mental health services.

Major medical organizations including the American Academy of Pediatrics and the American Academy of Child and Adolescent Psychiatry declared a national emergency in child and adolescent mental health. Emergency department visits for suspected suicide attempts among adolescent girls had risen 51 percent during the pandemic. The declaration highlighted rising rates of depression, anxiety, and suicidal ideation among young people, driven by social media use, academic pressure, climate anxiety, and pandemic-related disruption.

Meta Platforms reached a settlement with 47 US states, the District of Columbia, and US territories, agreeing to pay up to 17.1 billion dollars in penalties over claims that its platforms endangered children through addictive design features -- the largest settlement to date in the litigation wave linking social media to the youth mental health crisis. Meta paid nearly 12 billion dollars up front, with an additional 5 billion contingent on settlements by other platforms including Snap, TikTok, and YouTube; the states had initially sought roughly 200 billion dollars. The deal also mandated design changes to Meta's platforms for minors. Meta disputed the characterization of its products as addictive, and debate continued over whether design mandates and payouts would meaningfully affect youth mental health outcomes.

On 4 September 2026, New Zealand's medicines regulator Medsafe granted approval for two psychiatrists to prescribe pharmaceutical-grade MDMA as part of supervised therapy for adults with severe post-traumatic stress disorder that had not responded to conventional treatments, making New Zealand only the second country after Australia in 2023 to authorize psychedelic-assisted therapy for PTSD. The approval was welcomed by Associate Health Minister David Seymour, who noted the condition was difficult to treat. The approach remained contested internationally: the United States FDA had rejected an application for MDMA-assisted therapy in 2024, citing concerns over clinical trial design and expectancy effects, and researchers continued to debate the durability of treatment benefits. New Zealand's decision marked a cautious expansion of psychiatric treatment options amid a global search for therapies for treatment-resistant mental illness.

The CDC's 2025 Youth Risk Behavior Survey, published as the Youth Health in Focus report on September 21, 2026, recorded the first broad improvement in US high school students' mental health after a decade of deterioration. Between 2023 and 2025, fewer students reported persistent sadness or hopelessness, poor mental health, seriously considering suicide, making a suicide plan, or attempting suicide. The reversal followed the youth mental health emergency declared in 2021 and years of policy responses including school-based interventions and social media restrictions. Researchers debated the causes, crediting factors from post-pandemic recovery and reduced social media use to changing survey participation, and noted that 10-year trends for persistent sadness remained worse than 2015 levels, keeping long-term concerns alive even as the immediate indicators turned positive.